Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Genprex, Inc.
Genprex, Inc. News
Feb 23, 2026 - prnewswire.com
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Feb 10, 2026 - prnewswire.com
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Genprex, Inc. Quantitative Score
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Genprex, Inc. Financials
Table Compare
Compare GNPX metrics with: | |||
|---|---|---|---|
Earnings & Growth | GNPX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GNPX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GNPX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GNPX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Genprex, Inc. Income
Genprex, Inc. Balance Sheet
Genprex, Inc. Cash Flow
Genprex, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Genprex, Inc. Executives
| Name | Role |
|---|---|
| Mark S. Berger | Chief Medical Officer |
| Ryan Confer | President, Chief Executive Officer, Chief Financial Officer & Director |
| Jack A. Roth | Chairman of Scientific & Medical Advisory Board |
| Suzanne Thornton-Jones | Senior Vice President of Regulatory Affairs & Quality |
| David Schloss | Senior Vice President of Human Resources |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mark S. Berger | Chief Medical Officer | 1955 | 532.01K | |
| Ryan Confer | President, Chief Executive Officer, Chief Financial Officer & Director | Male | 1982 | 509.84K |
| Jack A. Roth | Chairman of Scientific & Medical Advisory Board | -- | ||
| Suzanne Thornton-Jones | Senior Vice President of Regulatory Affairs & Quality | -- | ||
| David Schloss | Senior Vice President of Human Resources | Male | -- |
Genprex, Inc. Insider Trades
| Date | 27 Feb |
| Name | Berger Mark Stanley |
| Role | Chief Medical Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 7168 |
| Date | 27 Feb |
| Name | Confer Ryan M. |
| Role | President, CEO and CFO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 9330 |
| Date | 22 Dec |
| Name | Moreno Toscano Jose Antonio |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 9000 |
| Date | 22 Dec |
| Name | Berger Mark Stanley |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 28500 |
| Date | 22 Dec |
| Name | Confer Ryan M. |
| Role | President, CEO and CFO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 45000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 27 Feb | Berger Mark Stanley | Chief Medical Officer | Disposed | F-InKind | 7168 |
| 27 Feb | Confer Ryan M. | President, CEO and CFO | Disposed | F-InKind | 9330 |
| 22 Dec | Moreno Toscano Jose Antonio | Director | Acquired | A-Award | 9000 |
| 22 Dec | Berger Mark Stanley | Chief Medical Officer | Acquired | A-Award | 28500 |
| 22 Dec | Confer Ryan M. | President, CEO and CFO | Acquired | A-Award | 45000 |